| 0.2761 0 (0.04%) | 10-04 09:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.37 |
1-year : | 0.42 |
| Resists | First : | 0.31 |
Second : | 0.36 |
| Pivot price | 0.28  |
|||
| Supports | First : | 0.25 | Second : | 0.2 |
| MAs | MA(5) : | 0.29 |
MA(20) : | 0.28 |
| MA(100) : | 0.4 |
MA(250) : | 0.69 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 50.4 |
D(3) : | 61.6 |
| RSI | RSI(14): 40.9 |
|||
| 52-week | High : | 1.67 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CARA ] has closed above bottom band by 31.0%. Bollinger Bands are 66.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.29 - 0.29 | 0.29 - 0.29 |
| Low: | 0.27 - 0.27 | 0.27 - 0.27 |
| Close: | 0.27 - 0.28 | 0.28 - 0.28 |
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Thu, 18 Jul 2024
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34% - Simply Wall St
Thu, 11 Jul 2024
Cara Therapeutics Announces Exploration of Strategic Alternatives - Yahoo Finance
Thu, 13 Jun 2024
Why Is Cara Therapeutics (CARA) Stock Down 27% Today? - InvestorPlace
Thu, 13 Jun 2024
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers' - Markets Insider
Thu, 13 Jun 2024
Cara Therapeutics stock downgraded by Stifel amid clinical setback - Investing.com
Wed, 12 Jun 2024
Cara Therapeutics Halts Trials for Itch Medication Difelikefalin - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 4.678e+007 (%) |
| Held by Institutions | 15.7 (%) |
| Shares Short | 1,460 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0472e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 636.1 % |
| Return on Equity (ttm) | -63.5 % |
| Qtrly Rev. Growth | 1.1e+007 % |
| Gross Profit (p.s.) | -122.43 |
| Sales Per Share | -263.32 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -80 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.92 |
| Dividend | 0 |
| Forward Dividend | 1.21e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|